India - Dexterous Laboratory for Global Clinical Trials

Mumbai 18th December, 2007: It gives comprehensive information on the current landscape of clinical trials in India. It thoroughly discusses the factors that are making India a favorable destination for clinical trial outsourcing together with regulatory environment and economic analysis of clinical trial phases.

The world’s one of the biggest emerging powers, India, is showing its presence in the field of clinical trials also. In recent times, the country has provided the favorable platform for conducting clinical trials and thus, is working for several international companies. Sensing the importance of India as a clinical trial hub, the leading market research firm Bharat Book Bureau has launched its report “Booming Clinical Trials Market in India” to give first-hand information on the Indian clinical trials market.

What make India a preferred destination globally to outsource clinical trials are its naļve patient populace, skilled medical professionals, attractive pharmaceutical market, industry-supportive regulations, and advanced technological infrastructure. Due to these promoters, Indian clinical trials market is projected to swell at a CAGR of around 35.5% from 2006 to 2011.

India is also fast becoming a hotspot for clinical data management. The Bharat Book research says that as India has a pool of skilled manpower with required IT expertise, therefore, it scores high over any other country for the outsourcing of clinical trial data management. Moreover, as India offers best clinical data management services at low cost, most of the US- and Europe-based multinational pharmaceutical companies are focusing on it.

But the biggest advantage of India is its large patient pool which can be recruited in much shorter time than its western counterparts, highlights the research. Recognizing the need of the hour, all leading Clinical Research Organizations (CROs) and pharmaceutical companies have already banged on with their clinical trials in India.

The Indian clinical trial industry is certainly in growth phase but to exploit its full potential and achieve seamless growth, the country needs to tackle issues like delay in trial approval process, lack of GCP (Good Clinical Practice)-certified investigators and site, and improper protection of clinical data, says the report.

“Booming Clinical Trials Market in India” gives comprehensive information on the current landscape of clinical trials in India. It thoroughly discusses the factors that are making India a favorable destination for clinical trial outsourcing together with regulatory environment and economic analysis of clinical trial phases. It chalks out the opportunity areas and challenges for the market and based on all these, augurs the future course of direction of the market.

About Bharat Book Bureau:

Bharat Book Bureau, leading information aggregator based in India, facilitates and supports the business information needs by providing relevant information on the Clinical Trial industry published by global agencies on Clinical Trial , etc. including country info, technical and management subjects, both in print and electronic format. These include reports, newsletters, country and company profile and online databases.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=70010

BharatBook.com is an aggregator of global business intelligence representing the most comprehensive collection of published market research available on-demand. Strategy starts with the most relevant, current and credible research available. Strategy starts here.

Bharat Book Bureau, 207, Hermes Atrium, Sector 11,
CBD Belapur, Navi Mumbai 400 614, India
Phone: (+9122 )27578668 , 27579438 Fax:(+9122 )27579131
email: info@bharatbook.com

Web Site : www.bharatbook.com

The world’s one of the biggest emerging powers, India, is showing its presence in the field of clinical trials also. In recent times, the country has provided the favorable platform for conducting clinical trials and thus, is working for several international companies. Sensing the importance of India as a clinical trial hub, the leading market research firm Bharat Book Bureau has launched its report “Booming Clinical Trials Market in India” to give first-hand information on the Indian clinical trials market. What make India a preferred destination globally to outsource clinical trials are its naļve patient populace, skilled medical professionals, attractive pharmaceutical market, industry-supportive regulations, and advanced technological infrastructure. Due to these promoters, Indian clinical trials market is projected to swell at a CAGR of around 35.5% from 2006 to 2011. India is also fast becoming a hotspot for clinical data management. The Bharat Book research says that as India has a pool of skilled manpower with required IT expertise, therefore, it scores high over any other country for the outsourcing of clinical trial data management. Moreover, as India offers best clinical data management services at low cost, most of the US- and Europe-based multinational pharmaceutical companies are focusing on it.
But the biggest advantage of India is its large patient pool which can be recruited in much shorter time than its western counterparts, highlights the research. Recognizing the need of the hour, all leading Clinical Research Organizations (CROs) and pharmaceutical companies have already banged on with their clinical trials in India. The Indian clinical trial industry is certainly in growth phase but to exploit its full potential and achieve seamless growth, the country needs to tackle issues like delay in trial approval process, lack of GCP (Good Clinical Practice)-certified investigators and site, and improper protection of clinical data, says the report.
“Booming Clinical Trials Market in India” gives comprehensive information on the current landscape of clinical trials in India. It thoroughly discusses the factors that are making India a favorable destination for clinical trial outsourcing together with regulatory environment and economic analysis of clinical trial phases. It chalks out the opportunity areas and challenges for the market and based on all these, augurs the future course of direction of the market.